Johnson & Johnson (NYSE:JNJ) Given Buy Rating at Guggenheim

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reissued by equities research analysts at Guggenheim in a research report issued on Wednesday, Marketbeat reports. They currently have a $287.00 price target on the stock. Guggenheim’s price objective would indicate a potential upside of 11.13% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday, August 3rd. Citigroup lifted their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Weiss Ratings raised shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Finally, TD Cowen increased their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $276.22.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $3.47 during mid-day trading on Wednesday, hitting $258.25. The stock had a trading volume of 5,277,043 shares, compared to its average volume of 7,981,148. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market cap of $622.35 billion, a price-to-earnings ratio of 29.92, a PEG ratio of 2.48 and a beta of 0.21. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The company’s 50 day simple moving average is $265.86 and its 200 day simple moving average is $248.63.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently added to or reduced their stakes in the stock. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $28,000. Matrix Trust Co lifted its holdings in Johnson & Johnson by 56.3% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $43,000. Hyposwiss Advisors SA acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $42,000. Finally, Polaris Financial Partners bought a new position in shares of Johnson & Johnson during the third quarter worth about $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 11% upside from the referenced trading level. RBC Capital also maintained its “Buy” rating. RBC Capital keeps its Buy rating on Johnson & Johnson
• Positive Sentiment: Multiple myeloma progress: Johnson & Johnson reported that the combination of Tecvayli and Talvey reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in the Phase 3 MonumenTAL-6 trial. The results support the potential expansion of J&J’s oncology portfolio, although the combination remains subject to regulatory and commercial development. 2026 cancer treatment advances
• Positive Sentiment: Psoriasis drug durability: Two-year Phase 3 data for oral ICOTYDE showed maintained skin clearance and consistent safety through Week 112, strengthening the case for the drug as a targeted treatment option in difficult-to-treat plaque psoriasis.
• Positive Sentiment: Innovative Medicines momentum: RBC commentary indicated that growth in J&J’s Innovative Medicine segment is helping offset weakness in MedTech, improving confidence in the company’s earnings and replacement-product pipeline. Innovative Medicines momentum
• Neutral Sentiment: Dividend appeal versus valuation: J&J recorded its 64th consecutive year of dividend growth, supporting its defensive-income profile. However, the investment case remains balanced against biosimilar competition, a MedTech slowdown and ongoing talc litigation. Johnson & Johnson dividend analysis
• Negative Sentiment: MedTech and patent-cliff risks: Analysts continue to watch competitive pressure, including Abiomed, and the possibility that upcoming patent expirations could test J&J’s ability to replace lost product revenue. J&J MedTech outlook

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.